Affymax
3.8 of 5 8 reviews
www.affymax.com Palo Alto, CA 50 to 149 Employees

Affymax Reviews

Be The First To
Add Photos

All Employees Current Employees Only

3.8 8 reviews

                             

100% Approve of the CEO

Affymax CEO and Director John Orwin

John Orwin

(1 ratings)

83% of employees recommend this company to a friend
3 Employee Reviews Back to all reviews
Relevance Date Rating
in
    • Culture & Values
           
    • Work/Life Balance
           
    • Senior Management
           
    • Comp & Benefits
           
    • Career Opportunities
           
    • Approves of CEO

     

    Good collaboration between departments, good benefits and bonuses.

    Anonymous Employee (Former Employee)
    Palo Alto, CA

    ProsSmart, intellectual workers, informative senior management from CEO to Director levels

    ConsOne product company, with no prospective pipeline. Lost good people during commercial product failure. Joint meetings between departments were often confrontational, and difficult to sit for several hours.

    Advice to Senior ManagementHave better clinical folks that can interpret patient data

    Yes, I would recommend this company to a friend – I'm optimistic about the outlook for this company

    Was this review helpful?
    Yes | No
    Add Employer Response Flag Review
    • Work/Life Balance
           
    • Senior Management
           
    • Comp & Benefits
           
    • Career Opportunities
           
    • Approves of CEO

     

    Future for Affymax after Hematide is murky

    Research Associate IV (Former Employee)
    Palo Alto, CA

    ProsIt has a peptide drug for anemia that is likely to be approved by the FDA. The drug has efficacy, low cost of goods, and is a good candidate for Medicare preference for the treatment of anemia for the dialysis patient population. The safety profile and monthly administration of the drug is a big advantage over the currently marketed drugs for anemia.

    ConsNo more research for new targets for new drugs in the pipeline. All work was focused on the one drug; what is next? Unless a new target is identified, there isn't much for people at Affymax to do. They already laid off 95% of the researchers, so all that history and expertise is gone. It seems to be solely focused on getting Hematide through the trials, and now that they are ready to submit data to the FDA, what happens to anyone who isn't in sales and marketing?

    Advice to Senior ManagementSell the company to Takeda and make some money for the stockholders, or start up R&D again. The latest worry about cardiovascular effects really caused the stock to tank. Can it be explained, or are there changes that can be made in the administration of Hematide that would ameliorate that effect? Try some positive spin in the marketing approach.

    Was this review helpful?
    Yes | No
    Add Employer Response Flag Review
    • Work/Life Balance
           
    • Senior Management
           
    • Comp & Benefits
           
    • Career Opportunities
           
    • No Opinion of CEO

     

    Fair

    Anonymous Employee (Former Employee)

    ProsGood industry to be in

    ConsPoor management at senior levels

    Advice to Senior ManagementDon't be so hierarchical with your technical staff

    Was this review helpful?
    Yes | No
    Add Employer Response Flag Review
RSS Feed Embed

Worked for Affymax? Contribute to the Community!

Your response will be removed from the review – this cannot be undone.

Glassdoor is your free inside look at Affymax reviews and ratings — including employee satisfaction and approval rating for Affymax CEO John Orwin. All reviews posted anonymously by Affymax employees.